Table 1 Baseline demographics and clinical data of the two treatment groups
30%-Dose PDT Group | 50%-Dose PDT Group | P value | |
|---|---|---|---|
(n = 21) | (n = 51) | ||
Age, mean ± SD, years | 44.90 ± 8.83 | 48.55 ± 1107 | > 0.5 |
Gender (male/female) | 17/4 | 40/10 | > 0.5 |
Duration of symptoms, (mean ± SD), months) | 8.5 ± 4.2 | 9.2.5 ± 6.2 | > 0.5 |
History of systemic steroid use, yes number. (%) | 3(14.28) | 5(10) | > 0.5 |
IOP, mean ± SD, mm Hg | 13.9 ± 2.6 | 14.3 ± 3.2 | > 0.5 |
BCVA, mean ± SD (ETDRS letters) | 72.4 ± 3.9 | 74.4 ± 4.2 | > 0.5 |
CRT, mean ± SD, µm | 365.7 ± 97.5 | 382.5 ± 131.2 | > 0.5 |
SRFT, mean ± SD, µm | 181.8 ± 89.9 | 203.5 ± 132.7 | > 0.5 |
SRCT, mean ± SD, µm | 242.9 ± 45.0 | 228.3 ± 48.9 | > 0.5 |
Hyperreflective foci yes number. (%) | 12(57.1) | 28(54.9) | > 0.5 |
Pigment epithelial detachment, yes number. (%) | 6(28.5) | 13(25.4) | > 0.5 |
Ellipsoid zone disruption yes number. (%) | 8(38.0) | 16(31.3) | > 0.5 |
Mean ± SD PDT spot size (µm) | 3200 ± 341 | 3300 ± 213 | > 0.5 |